Delving into the Latest Updates on Adalimumab-ATTO(Amgen) with Synapse

Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.

Start Date04 Oct 2021

Sponsor / Collaborator

Amgen, Inc.

NCT05909852

/ CompletedPhase 1

A Randomized, Single-blind, Single-dose, 2-arm, Parallel-group Study to Determine the Pharmacokinetic Comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF) in Healthy Adult Subjects

To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the serum concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and maximum observed serum concentration (Cmax) in healthy adult participants.

Start Date23 Jul 2021

Sponsor / Collaborator

Amgen, Inc.

NCT04131322

/ TerminatedPhase 4IIT

Loss of Response of Adalimumab Biosimilar Compared With the Loss of Response of Adalimumab Original: Controlled, Randomized, Non-inferiority Open Study. "ADA-SWITCH Study"

Loss of response of the Adalimumab biosimilar compared with the original drug.

Start Date10 Oct 2019

Sponsor / Collaborator

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

100 Clinical Results associated with Adalimumab-ATTO(Amgen)

Login to view more data

100 Translational Medicine associated with Adalimumab-ATTO(Amgen)

Login to view more data

100 Patents (Medical) associated with Adalimumab-ATTO(Amgen)

Login to view more data

69

Literatures (Medical) associated with Adalimumab-ATTO(Amgen)

01 Jan 2026·Crohns & Colitis 360

Effectiveness and safety of adalimumab biosimilar in bio-naive patients with inflammatory bowel disease: a real-life multicenter observational study comparing ABP501, SB5, MSB11022, GP2017, and FKB327.

Article

Author: Villaamil, Pablo Vega ; Regueiro, Cristina ; Ruiz Barcia, Maria Jesús ; Baz López, Alina Montserrat ; Bastón-Rey, Iria ; Campos, Amalia Carmona ; Arriero, Gema Molina ; Vázquez Rey, Maria Teresa ; Galego, Monica Ayude

Background:

Biosimilars represent a significant opportunity in the treatment of inflammatory bowel disease (IBD). Our aim is to assess the effectiveness and safety of the five approved adalimumab (ADA) biosimilars in IBD patients naive to biologics.

Methods:

IBD patients naive to biologics from eight Spanish hospitals were enrolled. We included patients who started ADA biosimilars between November 2018 and January 2022. The study endpoints included (1) induction of remission at week 8; (2) drug persistence at the conclusion of the follow-up period; and (3) safety of the five ADA biosimilars.

Results:

In total, 383 patients were included. After induction, 63.8% of patients were in clinical remission. In total, 114 (29.8%) patients discontinued treatment during follow-up. Clinical remission was maintained in 78.4% of patients after a median follow-up of 18 (12-24) months. Dose intensification was performed in 35 (9.1%) patients during follow-up. There was no significant difference in effectiveness for the 5-ADA biosimilars. Additionally, drug persistence was significantly higher in Crohn's disease (CD) patients (P = .012), in the group of patients co-treated with immunomodulators (IMM) (P = .001) and in patients with post-induction (at week 8) ADA levels ≥ 7 μg/mL (P = .002). Adverse events were reported in 30 (7.8%) patients with no significant difference between ADA biosimilars.

Conclusion:

ADA biosimilars are safe and effective in inducing and maintaining remission in a real-life population of bio-naive IBD patients. Furthermore, there is no significant difference between the 5-ADA biosimilars. Drug persistence was significantly higher in patients with CD treated with IMM and with post-induction ADA levels ≥7 μg/mL.

03 Oct 2025·EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritis

Article

Author: Niu, Fang ; Lin, Antony T-H ; Londa, Abbey ; Teshima, Samantha ; Hui, Rita L. ; Delate, Thomas ; Pham, Catherine

BACKGROUND:

Limited real-world studies have evaluated outcomes after switching treatment from a reference product (RP) to a biosimilar product. The objective of this real-world study was to assess the outcomes of switching from RP adalimumab to biosimilar adalimumab-atto in patients with rheumatoid arthritis (RA).

RESEARCH DESIGN AND METHODS:

This was a propensity score matched, non-inferiority study assessing adult patients with RA who switched from RP adalimumab to adalimumab-atto (Switchers) between or received RP adalimumab continuously (Non-Switchers). One-year disease worsening, serious adverse events, and patient out-of-pocket cost outcomes were evaluated. An upper limit of 5% for adalimumab-atto was set as the non-inferiority margin.

RESULTS:

After matching, there were 1,172 patients in each group. 24.8% and 31.0% of patients in the Switcher and Non-Switcher groups, respectively, experienced the disease worsening (non-inferiority p < 0.01). The crude rates per 100 patient-years of the safety outcome and mean monthly changes in out-of-pocket costs were 5.6 (95% CI 4.2-7.5) and 7.2 (95% CI 5.2-9.2) (p = 0.21) and -$51 (±$164) and -$11 (±$152) (p < 0.01) in the Switcher and Non-Switcher groups, respectively.

CONCLUSIONS:

These results provide evidence that switching from RP adalimumab to biosimilar adalimumab-atto did not result in disease worsening or increased adverse events but did deliver modestly lower patient out-of-pocket costs.

01 Sep 2025·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

Article

Author: Ferguson, John ; Rabbitt, Louise ; Keogh, Áine ; McGuire, Brian E. ; Duane, Linda ; Hobbins, Anna ; Egan, Laurence J. ; Gillespie, Patrick

Aims:

Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes and associated psychosocial variables in a group of patients undergoing a nonmedical switch to biosimilar adalimumab.

Methods:

Patients with inflammatory bowel disease (IBD) were followed before and after switching from Humira to Amgevita. Objective disease activity was assessed pre‐ and post‐switch using the Harvey–Bradshaw Index (Crohn's disease) or partial Mayo score (ulcerative colitis), faecal calprotectin and C‐reactive protein. Subjective symptom burden was measured using the IBD Control Questionnaire (IBDCQ). Pre‐switch, health anxiety was measured using the Health Anxiety Index (HAI).

Results:

In total, 64 patients aged 18–67 were enrolled. IBDCQ scores marginally improved post‐switch (13.33 vs , 12.49, P = .043), with no significant changes in objective disease activity scores, faecal calprotectin or C‐reactive protein. Sixteen patients reported 17 new adverse events within 4 weeks. Logistic regression revealed a significant relationship between HAI scores and adverse events ( P = .0079); each unit increase in HAI score increased the odds of reporting an adverse event by 21%. Drug cost savings for the 64 patients over 8 weeks totalled €143 958.

Conclusion:

Switching to biosimilar adalimumab did not affect disease control or quality of life. 25% of patients developed new side effects, particularly those with high levels of health anxiety. Significant cost savings were achieved.

153

News (Medical) associated with Adalimumab-ATTO(Amgen)

07 Apr 2026

·firstwordpharma.com

Biopharma bites: New additions to TrumpRx, a suite of deals from Biogen, Lilly and Vertex, plus Renovare's launch

Humira joins its biosimilars on TrumpRxBiogen joins forces with Alloy on antisense platformLilly amends tau tie-up with AC ImmuneVertex partners with Halozyme on drug-delivery techRenovare launches to develop regenerative osteoarthritis therapiesHumira joins its biosimilars on TrumpRxAbbVie's former megablockbuster Humira (adalimumab) has made its debut on TrumpRx, where patients can purchase a month's supply of the anti–TNF-α mAb for $950 in cash. While the pricetag is an 86% discount from Humira's nearly-$7000 list price, the government-run direct-to-consumer (DTC) site also offers a pair of Humira biosimilars at half, or less, the price of the name-brand autoimmune disease drug. Pfizer's biosimilar, Abrilada (adalimumab-afzb) is available for $415.20 per month, and Amgen's Amjevita (adalimumab-atto) has a monthly cash-pay price of $299.Meanwhile, Gilead's flu medication, Xofluza (baloxavir marboxil), was also listed on TrumpRx this week for $50, matching the cash-pay price offered on the drugmaker's DTC platform.-Elizabeth EatonBiogen joins forces with Alloy on antisense platformAs part of a deal announced Tuesday, Biogen will use Alloy Therapeutics' AntiClastic antisense oligonucleotide (ASO) platform to advance antisense therapeutics against multiple undisclosed targets. Alloy is eligible to receive an undisclosed upfront payment, as well as milestones and tiered royalties on products resulting from the collaboration.The AntiClastic ASO platform is designed to address potency and therapeutic index challenges that have historically held back the promise of antisense drugs due to limited biodistribution. Alloy noted that the platform enables drug developers to realise the full potential of antisense therapeutics by reaching intracellular disease targets at the RNA level. "This collaboration reflects Biogen's commitment to pushing the boundaries of scientific innovation and exploring novel approaches to address complex diseases," said Jane Grogan, Biogen's head of research.-Matthew DennisLilly amends tau tie-up with AC ImmuneEli Lilly and AC Immune have amended their 2018 collaboration to develop small molecule tau aggregation inhibitors for Alzheimer's disease and other neurodegenerative disorders, adding new lead and back-up Morphomer Tau candidates — which are able to enter the brain when dosed orally and bind to the protein's pathological conformation — to the collaboration. According to AC Immune, Morphomer small molecules can target intracellular tau, and "strong preclinical data" suggest they "should be clinically relevant for inhibiting aggregation and seeding across pathological and disease stages." IND-enabling studies are slated to begin this half.Under the amended deal, AC Immune will receive CHF10 million ($12.5 million) upfront and an extra milestone payment upon Phase I dosing, in addition to milestones announced in a previous deal revision. The company remains eligible for further development, regulatory and commercial milestones exceeding CHF1.7 billion ($2.1 billion), along with tiered royalty payments.-Anna BratulicVertex partners with Halozyme on drug-delivery techVertex Pharmaceuticals has licensed Halozyme Therapeutics' Hypercon microparticle technology for use in up to three drug targets, the companies announced Tuesday. "We are pleased to add…[the] drug-delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases," said Mark Bunnage, chief scientific officer of Vertex.The Hypercon technology allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling at-home administration. The technology has previously been licensed to argenx, Eli Lilly and Johnson & Johnson's Janssen unit.Under the deal, Vertex will make a $15 million upfront payment to Halozyme and is on the hook for undisclosed milestones, with the latter also entitled to sales royalties on products developed using the Hypercon technology.-Matthew DennisRenovare launches to develop regenerative osteoarthritis therapiesRenovare Therapeutics emerged from stealth on Monday, announcing a collaboration with the University of Colorado (CU) Boulder under a US government contract worth up to $33.5 million to develop regenerative treatments for osteoarthritis.The funding, awarded by the Advanced Research Projects Agency for Health (ARPA-H) under its Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) programme, will support IND-enabling and Phase I safety studies for Renovare's lead assets. These therapies aim to be regenerative, potentially halting and reversing disease progression."With Renovare’s technologies having broad applicability beyond osteoarthritis, we are excited to build a biotechnology company of significant value to patients, providers, and community stakeholders," said CEO Liz Scott.-Pavan Kamat

License out/inPhase 1

27 Mar 2026

·allsci.com

Soligenix’s dusquetide granted EC Orphan Drug Designation for Behçet’s disease

Soligenix (Nasdaq: SNGX) announced that the European Commission granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet’s Disease. The designation follows a positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). In the EU, orphan drug designation provides a 10-year period of marketing exclusivity following product approval, along with incentives including protocol assistance from the EMA and direct access to the centralized authorization procedure. SGX945 previously received orphan drug designation and Fast Track designation from the U.S. Food and Drug Administration (FDA) for Behçet’s Disease, as well as Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Dusquetide, the active ingredient in SGX945, is a synthetic peptide classified as an innate defense regulator (IDR). Rather than targeting a single receptor, it modulates innate immune system responses toward anti-inflammatory and tissue-healing pathways. The EMA designation was granted following review of Phase IIa clinical results in eight patients with Behçet’s Disease. In that open-label study, the primary endpoint — area under the curve (AUC) of the mean number of oral ulcers versus time — showed a 40% improvement relative to the placebo arm from the Phase III apremilast registration study after four weeks of treatment. The improvement was sustained at 32% through a four-week follow-up period after treatment cessation. No treatment-related adverse events were reported. No active or recruiting clinical trials for dusquetide in Behçet’s Disease are currently listed in major public registries. The only approved therapy for oral ulcers in Behçet’s Disease is apremilast (Otezla), a phosphodiesterase 4 (PDE4) inhibitor marketed by Amgen. Apremilast requires continuous administration and carries a side-effect profile that includes diarrhea (41% of patients), nausea (19%), and headache (14%) based on its registration data. Dusquetide operates through a distinct mechanism — innate immune modulation rather than PDE4 inhibition — and the Phase IIa data showed none of these gastrointestinal or neurological adverse events. The current treatment landscape otherwise relies on corticosteroids, immunosuppressants such as azathioprine and cyclosporine, and TNF inhibitors including infliximab and adalimumab for severe or refractory cases. Apremilast remains the only specifically approved drug for oral ulcers in Behçet’s disease. Behçet’s disease affects an estimated 18,000 people in the US, over 50,000 in Europe, and up to 1 million worldwide, with prevalence concentrated along the historical Silk Road region. The condition meets EU orphan disease criteria at fewer than 5 in 10,000 persons. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultOrphan DrugPhase 2Drug ApprovalFast Track

17 Mar 2026

·firstwordpharma.com

Biopharma bites: A trio of drugs join TrumpRx, BioMarin stops several studies, plus paediatric proof for Lilly's Ebglyss

Drugs from Amgen, GSK join TrumpRxBioMarin stops certain skeletal studies after safety signalLilly's Ebglyss passes paediatric testDrugs from Amgen, GSK join TrumpRxTrumpRx, a direct-to-consumer (DTC) platform run by the US government, welcomed three new products to its site on Monday, according to a post on X from the White House. Amgen is offering its migraine medicine Aimovig (erenumab), as well as Amjevita (adalimumab-atto) — its biosimilar of AbbVie's Humira (adalimumab) — for a monthly cash-pay price of $299 each. GSK's Incruse Ellipta (umeclidinium), an inhaled treatment for chronic obstructive pulmonary disease (COPD), is available for $159.20 per month on TrumpRx for self-pay patients. The three additions to TrumpRx come after the website officially launched in February with price cuts for about 43 medications.Both pharmas, along with seven other drugmakers, agreed in December to sell some of their products on DTC sites as part of a most favoured nation drug pricing agreement with the Trump administration. -Elizabeth EatonBioMarin stops certain skeletal studies after safety signalBioMarin disclosed in a securities filing Monday that, following a safety signal in a pair of investigator-sponsored trials, it has halted its own Phase II studies evaluating Voxzogo (vosoritide) in patients with certain skeletal conditions. The drugmaker said that "several" cases of slipped capital femoral epiphysis (SCFE) occurred in the investigator-sponsored trials. As a result, it will discontinue dosing and enrollment in its studies involving patients with Turner syndrome, SHOX-deficiency and ACAN-deficiency. BioMarin emphasised that SCFE events have not been observed in its trials of these indications, nor in any of its achondroplasia or hypochondroplasia studies. The Phase II CANOPY trial evaluating Voxzogo in children with Noonan syndrome, as well as those living with idiopathic short stature (ISS) without ACAN-deficiency, will continue unaffected. The FDA approved Voxzogo for achondroplasia in 2021; since then, the company has made expanding the modified C-type natriuretic peptide's label into additional skeletal conditions central to its growth strategy. Before Monday's setback, BioMarin had been targeting five new indications for Voxzogo by 2031, including hypochondroplasia, ISS, Noonan syndrome, Turner syndrome and SHOX deficiency. -Elizabeth EatonLilly's Ebglyss passes paediatric testEli Lilly's Ebglyss (lebrikizumab-lbkz) met the primary and key secondary endpoints of the Phase III ADorable-1 trial in paediatric patients with moderate-to-severe atopic dermatitis. The company plans to submit the data to the FDA and other regulators for a potential update to the IL-13 inhibitor's label.Top-line results showed that 63% of patients on Ebglyss achieved meaningful skin improvement at week 16, as measured by a 75% improvement in the Eczema Area and Severity Index (EASI) from baseline, and 44% achieved clear or almost clear skin on the Investigator's Global Assessment (IGA). For patients taking placebo, 22% achieved EASI-75 and 15% had clear or almost clear skin based on IGA."Ebglyss has already changed what's possible for adults and adolescents," said Adrienne Brown, president of Lilly Immunology. "Now, these data show Ebglyss also provided disease control in paediatric patients."The company has rights to Ebglyss in all markets, except Europe, where Almirall has licensed rights for all dermatology indications, including atopic dermatitis.-Matthew Dennis

Clinical ResultPhase 3Phase 2Drug Approval

100 Deals associated with Adalimumab-ATTO(Amgen)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Adalimumab-ATTO(Amgen)	L04AB04	DB00051

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Non-radiographic axial spondyloarthritis	Japan	Daiichi Sankyo Co., Ltd.	19 Mar 2025
Panuveitis	Japan	Daiichi Sankyo Co., Ltd.	16 Feb 2022
Uveitis, Intermediate	Japan	Daiichi Sankyo Co., Ltd.	16 Feb 2022
Uveitis, Posterior	Japan	Daiichi Sankyo Co., Ltd.	16 Feb 2022
Crohn's disease, active moderate	Japan	Daiichi Sankyo Co., Ltd.	25 Aug 2021
Crohn's disease, active severe	Japan	Daiichi Sankyo Co., Ltd.	25 Aug 2021
Behcet's uveitis	Japan	Daiichi Sankyo Co., Ltd.	22 Jan 2021
Pustular psoriasis	Japan	Daiichi Sankyo Co., Ltd.	22 Jan 2021
Ulcerative colitis, active moderate	Japan	Daiichi Sankyo Co., Ltd.	22 Jan 2021
Ulcerative colitis, active severe	Japan	Daiichi Sankyo Co., Ltd.	22 Jan 2021
Axial Spondyloarthritis	European Union	Amgen Europe BV	21 Mar 2017
Axial Spondyloarthritis	Iceland	Amgen Europe BV	21 Mar 2017
Axial Spondyloarthritis	Liechtenstein	Amgen Europe BV	21 Mar 2017
Axial Spondyloarthritis	Norway	Amgen Europe BV	21 Mar 2017
Enthesitis-Related Arthritis	European Union	Amgen Europe BV	21 Mar 2017
Enthesitis-Related Arthritis	Iceland	Amgen Europe BV	21 Mar 2017
Enthesitis-Related Arthritis	Liechtenstein	Amgen Europe BV	21 Mar 2017
Enthesitis-Related Arthritis	Norway	Amgen Europe BV	21 Mar 2017
Hidradenitis Suppurativa	European Union	Amgen Europe BV	21 Mar 2017
Hidradenitis Suppurativa	Iceland	Amgen Europe BV	21 Mar 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	United States	Amgen, Inc.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05073315 (CTgov)	Phase 3	Plaque psoriasis	425	adalimumab (Period 2 (Switching Group))	nexobnuvhi(vcvcndculs) = syqqiqxakj dlloxbnlxv (qqvdoqbeha, 156.6) View more	-	09 Feb 2024
				adalimumab (Period 2 (Continued-use Group))	nexobnuvhi(vcvcndculs) = zpjepzgrlw dlloxbnlxv (qqvdoqbeha, 174.9) View more
AAD2023	Not Applicable	Psoriasis	-	ABP501	pwmburdxqh(wwtewivgfd) = mnnllkumcv pjkmoxojfw (ktnuuwnqyy, 8.1 - 13.0)	-	17 Mar 2023
				Reference product (RP) or other ADA biosimilars	pwmburdxqh(wwtewivgfd) = efhhmzsaqb pjkmoxojfw (ktnuuwnqyy, 7.0 - 9.8)
AAD2023	Not Applicable	Psoriasis	271	Adalimumab Biosimilar (ABP 501)	uiysvzvlfq(hjljiuoktr) = qaxvvhnpdr eghgowazll (jjmkntqjvy ) View more	-	17 Mar 2023
				Adalimumab Biosimilar (ABP 501)	uiysvzvlfq(hjljiuoktr) = erkurhxrcr eghgowazll (jjmkntqjvy ) View more
SPOSAB ABP 501 (UEGW2020)	Not Applicable	Inflammatory Bowel Diseases	559	ADALIMUMAB BIOSIMIADA ABP 501 (Group A: naive to ADA and naive to anti-TNFs)	mbmvfaenif(wcsdubavjw) = fmifvbkblp wjgdezzlmc (nsnhnavico ) View more	Positive	01 Oct 2020
				ADALIMUMAB BIOSIMILAR ABP 501 (Group B: naive to ADA and previously exposed to anti-TNFs)	opecfmfbvv(mcjtvxqfui) = jgzyjpffwx jlklfwovyw (frotopugve )
NCT01970475 (EULAR2019)	Phase 3	Rheumatoid Arthritis adalimumab \| anti-adalimumab antibodies	30	ABP 501	rgtipqmalw(wortlgoexu) = zdrpforkkt nrmxnxlyrv (xafuehxihv )	-	12 Jun 2019
NCT02114931 (Pubmed \| J Rheumatol \| Arthritis Res Ther) Manual	Phase 3	Rheumatoid Arthritis	466	ABP 501	-	Positive	29 Mar 2019
				ABP 501+adalimumab
UEGW2018	Phase 3	Plaque psoriasis	-	ABP 501	adessnxkxw(dgfcgeyrht) = wdazjmxrvp efnwbxjiqk (xnkeogzbfu ) View more	Positive	01 Oct 2018
				Adalimumab RP	adessnxkxw(dgfcgeyrht) = ewjfynyqmf efnwbxjiqk (xnkeogzbfu ) View more
UEGW2018	Phase 3	-	-	ABP 501	adzehimkha(ajskhightb) = qxemvvinni hvsljizhkt (iujnsmqiww ) View more	Positive	01 Oct 2018
				Adalimumab (RP)	adzehimkha(ajskhightb) = xhuaqvgdgn hvsljizhkt (iujnsmqiww ) View more
UEGW2018	Phase 3	Psoriasis	347	ABP 501	sqbswatsmj(stptuxnbdb) = rpfazpejic roetdlkwrk (dxepsldukt ) View more	Positive	01 Oct 2018
				Adalimumab RP	sqbswatsmj(stptuxnbdb) = ffqfjhrost roetdlkwrk (dxepsldukt ) View more
EULAR2018	Not Applicable	Rheumatoid Arthritis	-	ABP 501	mqostrdido(ewrlszyykp) = vdvplwjgny bfnvenvyjk (udwexewrwc ) View more	-	13 Jun 2018
				Adalimumab reference product	mqostrdido(ewrlszyykp) = mxbfpzjfet bfnvenvyjk (udwexewrwc ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Adalimumab-ATTO(Amgen)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation